Kazia Therapeutics Limited ADR(KZIA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.82 | Insider Own | 14.01% | Shs Outstand | 11.3M | Perf Week | 9.99% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | -56.41% | Insider Trans | - | Shs Float | 9.8M | Perf Month | -9.29% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.07 | Inst Own | 41.39% | Short Float | 13.31% | Perf Quarter | -30.78% |
| Income | -0.01B | P/S | 3272.79 | EPS this Y | 23.08% | Inst Trans | 16.36% | Short Ratio | 4.79 | Perf Half Y | -35.85% |
| Sales | 0.00B | P/B | 3.14 | EPS next 5Y | -10.6% | ROA | -50.34% | Short Interest | 1.31M | Perf YTD | 24.67% |
| Book/sh | 2.73 | P/C | 2.12 | EPS past 3/5Y | 43.68% 25.92% | ROE | -102.88% | 52W High | -50.63% ($17.40) | Perf Year | 11.85% |
| Cash/sh | 4.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.53% | 52W Low | 76.75% ($4.86) | Perf 3Y | -67.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 76.83% | Gross Margin | - | Volatility(W/M) | 7.51% 8.15% | Perf 5Y | -98.41% |
| Dividend TTM | - | EV/Sales | 1731.12 | Sales Y/Y TTM | -98.25% | Oper. Margin | -49070.5% | ATR (14) | 0.72 | Perf 10Y | -97.17% |
| Dividend Ex-Date | - | Quick Ratio | 2.87 | EPS Q/Q | 67.55% | Profit Margin | -55271.07% | RSI (14) | 47.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.87 | Sales Q/Q | - | SMA20 | 3.86% ($8.27) | Beta | 2.35 | Target Price | $31.14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/04 | SMA50 | -16.05% ($10.23) | Rel Volume | 0.84 | Prev Close | $8.72 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -18.54% ($10.55) | Avg Volume(3M) | 0.27M | Price | $8.59 |
| IPO | 1999/1/6 | Option/Short | Yes/Yes | Trades | 1227 | Volume | 230,440 | Change | -1.49% |
🧬 Kazia Therapeutics is a clinical-stage pharmaceutical company specializing in oncology, with a focus on brain tumors. Founded in Australia, it is listed on the Nasdaq via American Depositary Receipts (ADRs) and is developing novel drug candidates targeting hard-to-treat cancers such as glioblastoma. As a pre-commercialization, clinical-stage company, it is a typical small-cap biotech whose share price reacts sensitively to pipeline progress updates.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
KZIA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +23.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $327,279. Peers typically go for $1,089.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 41.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
APIE ActivePassive International Equity ETF <0.01% It ranks #358 of 595 in the industry
Based on market cap of $98M.
CBUS#354 Cibus Inc $99M PER - 
PMVP#355 PMV Pharmaceuticals Inc $99M PER - 
VANI#356 Vivani Medical Inc $98M PER - 
NRXP#357 NRX Pharmaceuticals Inc $98M PER - KZIA#358 Kazia Therapeutics Limited ADR $98M PER - 
FAQ
What kind of company is KZIA?
KZIA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KZIA?
The market cap of KZIA is approximately $98M, ranking 4,471 within its sector.
What is the 52-week high and low for KZIA?
KZIA has recorded a 52-week high of $17.40 and a low of $4.86.
